Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
Introduction The approval of the esketamine nasal spray for treatment-resistant depression in March 2019 by the Food and Drug Administration (FDA), and few months later by the European Medicine Agency, triggered a vivid debate and many concerns, mainly because of the lack of convincing evidence on...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Cambridge University Press
2021-04-01
|
| סדרה: | European Psychiatry |
| נושאים: | |
| גישה מקוונת: | https://www.cambridge.org/core/product/identifier/S0924933821004107/type/journal_article |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|